University of Oklahoma
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Oklahoma sits in the top decile of US sponsors by registered trial count (#100 of 15,742 sponsors by registered trial count).
University of Oklahoma: 358 sponsored US clinical trials, 80 recruiting.
University of Oklahoma sponsors 358 registered US clinical trials on ClinicalTrials.gov, 80 of them currently recruiting, and 196 completed. 26 of these trials are in Phase 3-4 (later-stage) and 88 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 6 trials.
Top-decile sponsor footprint
University of Oklahoma ranks in the top decile of sponsors by registered trial count (#100 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
196 of 240 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
358 total, page 5 of 8
Effect of Transcutaneous Vagal Stimulation (TVS) on Endothelial Function in PAD
NCT03445754
Effect of Transcutaneous Vagal Stimulation (TVS) on Endothelial Function and Arterial Stiffness in HFrEF
NCT03380156
Recurrent Urinary Tract Infections and Heparin (RUTIH Trial)
NCT02246270
Spectral Analysis Probe to Identify Glioblastoma Cells
NCT03293888
Vaginal Cuff Brachytherapy Followed by Chemotherapy in Endometrial Cancer
NCT03189446
Technical Assistance for Child and Adult Care Food Program in Family Child Care Home
NCT03560050
Unesbulin in Women With Ovarian Cancer Receiving Neoadjuvant Chemotherapy
NCT03206645
Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary
NCT03206177
Mass Spectrometry in Single Bladder Cancer Cells
NCT03639090
Prognostic Markers of Inflammation in Infants Undergoing Cardiopulmonary Bypass
NCT03143348
The Impact of Waterpipe Tobacco Flavors on Waterpipe Smoking Intentions, Perceptions, Patterns, and Toxicant Exposure
NCT03232827
Clinical Trial of an Automated Smartphone Based Smoking Cessation Treatment
NCT02930200
Smartphone-delivered Automated Video-assisted Smoking Treatment for Patrons of a Food Resource Center
NCT03060278
Smartphone-delivered Automated Video-assisted Smoking Treatment for People Living With HIV
NCT03082482
Use of Personal Fitness Device in Adult (> 21 Years Old) Patients With Cystic Fibrosis
NCT03122418
Foley Catheter Compared to the Foley Catheter Alone for Cervical Ripening
NCT03111316
Fluid Restriction in Respiratory Distress of the Newborn
NCT03120585
Vitamin D, Leptin, Vitamin D Receptor Polymorphism, and Treatment-Related Morbidity in Ovarian Cancer
NCT03028519
Small Financial Incentives to Promote Smoking Cessation
NCT02737566
Noninvasive Neuromodulation to Reserve Diastolic Dysfunction
NCT02983448
Transcutaneous Electrical Vagus Nerve Stimulation to Suppress Atrial Fibrillation
NCT02548754
Effect of Milk Warming on the Very Low Birth Weight Infant
NCT04282655
Use of Endobronchial Ultrasound Scope (EBUS) Transducer to Identify Pneumothorax-A Feasibility Study
NCT02907866
Tribal Health and Resilience in Vulnerable Environments
NCT03311217
Quality Control: A Prospective Analysis of EVD Effectiveness
NCT02484287
HFNC Effect on BCSS in Patients With COPD
NCT02825043
Intensive Management for Gestational Diabetes
NCT02530866
Compassionate Use of Omegaven in Children
NCT02370251
Effect of Protein Intake on Preterm Infant Body Composition
NCT02353013
EIMD Mechanisms Causing Force Loss
NCT02125643
The Effects of Caffeine on Pain-Based Pacing During a Cycling Time-Trial
NCT02115763
HIV Risk and Prevention in Women
NCT02263391
Fatty Acid Ethyl Esters in Meconium of Infants of Diabetic Mothers: a Pilot Trial
NCT02308735
Study of Eribulin in Children With Cancer to Determine Safety
NCT02082626
iSTAT Comparison Study, IRB3785
NCT02208895
Inferior Vena Cava (IVC) Size in Acute Renal Failure
NCT02064244
Diphenhydramine as an Adjunctive Sedative in Patients on Chronic Opioids
NCT01967433
Post-Operative Pain Management With NSAIDS
NCT01971372
Using an iPhone ECG to Monitor the QT Interval on Dofetilide and Sotalol Patients
NCT02241252
OCAST Cessation Study
NCT01921439
Smoking Cessation in Women With Gynecological Conditions
NCT01989923
Financial Incentives to Exercise for Adolescents
NCT01848353
DCLK1 as a Marker/Indicator of Stem Cell Response in Barrett's Esophagus/Esophageal Adenocarcinoma
NCT03526328
Aflibercept Injection for Proliferative Diabetic Retinopathy
NCT01805297
Expansion to Interdisciplinary HIV Prevention in Women
NCT01994603
Novel Methods to Reduce Children's Secondhand Smoke Exposure II
NCT01896518
Utility of Syringe Based Suction Versus Channel Suction in Bronchoalveolar Lavage
NCT01853904
Efficacy of Aprepitant (Emend®) in Children
NCT01661335
Registry and Fluid Banking of Pancreatic Cystic Lesions
NCT01769534
Preliminary Investigation of Novel Methods to Reduce Children's Secondhand Smoke Exposure
NCT01935713
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 48 |
| Phase 2 | 40 |
| Phase 3 | 8 |
| Phase 4 | 18 |
Therapeutic Areas
What is open in the University of Oklahoma pipeline
80 recruiting of 358 indexed (22% open); 196 completed (55%).
Phase mix: 26 late (III/IV) vs 88 early (I/II) (early-phase heavy).
Top condition: Prostate Cancer (6 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Oklahoma: open-pipeline peers nationwide
Peers matched on 358 registered trials and 22% open enrollment, not the therapeutic-area sidebar.
University of Oklahoma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 358 trials (± recruiting share)
- New York State Psychiatric Institute · 364 trials · 3% recruiting
- Roswell Park Cancer Institute · 365 trials · 16% recruiting
- UNC Lineberger Comprehensive Cancer Center · 366 trials · 22% recruiting
- University of Arizona · 349 trials · 16% recruiting
Sponsors near 22% open enrollment (± trial volume)
- ALX Oncology · 22% recruiting · 9 trials
- Biosense Webster · 22% recruiting · 18 trials
- Englewood Hospital and Medical Center · 22% recruiting · 18 trials
- Ensysce Biosciences · 22% recruiting · 9 trials
Related
What to do with this University of Oklahoma page
358 registered trials is a research-attention snapshot, not an endorsement of University of Oklahoma or any single study.
- 80 of University of Oklahoma's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Prostate Cancer is the condition University of Oklahoma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
University of Oklahoma pipeline card: 358 registered trials from official public datasets.Report a data error.